Study identifier:NIS-GGR-DUM-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A cross-sectional study on the prevalence and impact in work productivity of GERD in primary care patients with upper GI symptoms using the novel questionnaire GERD-Q. The Greek GERD-Q Study
Gastroesophageal Reflux Disease
N/A
No
-
All
889
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2015 by AstraZeneca
AstraZeneca
-
The purpose of the study is to provide data on the GERD prevalence as percentage of patients with upper GI symptoms that are identified with GERD using the GerdQ Questionnaire. Furthermore the study aims to estimate GERD prevalence in patients based on their symptoms as they respond to a physician’s questionnaire, to observe possible variations between the two methods (physicians’ symptom rating and GerdQ), to objectively measure treatment response and to identify the percentage of patients that may require alterations of their treatment. Finally, to describe the impact of GERD symptoms on work productivity.
Location
Location
Patras, Achaias, Greece
Location
Grinion, Aitoloakarnania, Greece
Location
Mesologgion, Aitoloakarnaniaia, Greece
Location
Aleksandroupoli, Aleksandroupoli, Greece
Location
Acharnes, Attiki, Greece
Location
Ag.Paraskeui, Attiki, Greece
Location
Chalandri, Attiki, Greece
Location
Glifada, Attiki, Greece
Arms | Assigned Interventions |
---|---|
Upper-GI symptoms in primary-care patients | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.